SCI Pharmtech (Taiwan) Insiders
| 4119 Stock | TWD 90.60 1.90 2.05% |
SCI Pharmtech employs about 14 people. The company is managed by 5 executives with a total tenure of roughly 33 years, averaging almost 6.0 years of service per executive, having 2.8 employees per reported executive. Recap of SCI Pharmtech's management performance can provide insight into the venture performance.
| JunBang Ye Insider VP |
| WenChih Chou Insider GM Pres |
SCI |
SCI Pharmtech Management Team Effectiveness
SCI Pharmtech's management efficiency ratios could be used to measure how well SCI Pharmtech manages its routine affairs as well as how well it operates its assets and liabilities.SCI Pharmtech Workforce Comparison
SCI Pharmtech is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 154. SCI Pharmtech holds roughly 14.0 in number of employees claiming about 9% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.26 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.07 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.07. SCI Pharmtech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. SCI Pharmtech Price Series Summation is a cross summation of SCI Pharmtech price series and its benchmark/peer.
SCI Pharmtech Notable Stakeholders
A SCI Pharmtech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as SCI Pharmtech often face trade-offs trying to please all of them. SCI Pharmtech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting SCI Pharmtech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| JunBang Ye | VP | Profile | |
| WenChih Chou | GM Pres | Profile | |
| Deiter Yang | CG Sec | Profile | |
| Michele Seah | VP | Profile | |
| Ricky Liu | Sustainable Mang | Profile |
About SCI Pharmtech Management Performance
The success or failure of an entity such as SCI Pharmtech often depends on how effective the management is. SCI Pharmtech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of SCI management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the SCI management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and specialty chemicals in Taiwan. SCI Pharmtech, Inc. was founded in 1987 and is based in Taoyuan City, Taiwan. SCI PHARMTECH operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.
Please note, the imprecision that can be found in SCI Pharmtech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SCI Pharmtech. Check SCI Pharmtech's Beneish M Score to see the likelihood of SCI Pharmtech's management manipulating its earnings.
SCI Pharmtech Workforce Analysis
Traditionally, organizations such as SCI Pharmtech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare SCI Pharmtech within its industry.SCI Pharmtech Manpower Efficiency
Return on SCI Pharmtech Manpower
| Revenue Per Employee | 61.7M | |
| Revenue Per Executive | 172.8M | |
| Net Income Per Employee | 4M | |
| Net Income Per Executive | 11.1M | |
| Working Capital Per Employee | 72.8M | |
| Working Capital Per Executive | 203.8M |
Additional Tools for SCI Stock Analysis
When running SCI Pharmtech's price analysis, check to measure SCI Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SCI Pharmtech is operating at the current time. Most of SCI Pharmtech's value examination focuses on studying past and present price action to predict the probability of SCI Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SCI Pharmtech's price. Additionally, you may evaluate how the addition of SCI Pharmtech to your portfolios can decrease your overall portfolio volatility.